rtx1 in clinical trial for stem-cell therapy for AMD

In a study published in Ophthalmology Retina, a team of researchers led by Prof. Masayo Takahashi (RIKEN, Japan) used the rtx1 Adaptive Optics Retinal Camera to assess novel cell-replacement therapy for Age-related Macular Degeneration (AMD).

AMD is a common cause of blindness. It starts by the degeneration of one type of retinal cells: the RPE cells. With the advent of stem-cell technologies, scientists and ophthalmologists started developing cell-replacement therapies to try and restore vision in AMD patients.

In an ongoing trial in Japan, a patient underwent a surgical procedure to replace damaged RPE cells by new RPE cells derived from stem cells. The transplant was then monitored during 4 years and results are reported in the article. Co-author Dr Seiji Takagi (Kobe City Eye Hospital, Japan) commented:

“The rtx1 allowed us to directly observe stem cell-derived RPE cells after their transplantation in a patient’s retina. Thanks to the rtx1’s microscopic resolution, we could verify that the mosaic arrangement of these cells was similar to that of natural RPE cells, and stable over time.

Read more about the rtx1 here.
Click here to see all rtx1 peer-reviewed articles.

Article reference: Takagi, S. Mandai, M. Gocho, K. et al. Evaluation of Transplanted Autologous Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium in Exudative Age-Related Macular Degeneration. Ophthalmology Retina S2468653019300909 (Jun. 2019)